These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 33187767)

  • 1. Safety biomarkers for development of vaccines and biologics: Report from the safety biomarkers symposium held on November 28-29, 2017, Marcy l'Etoile, France.
    Doubovetzky M; Ataman-Önal Y; Chousterman B; Feroldi E; Garçon N; Grillet MH; Kramer D; Laurent S; Lewis DJM; Luna E; Manigold T; Syntin P; Burdin N; Fraisse L; Jackson N
    Vaccine; 2020 Dec; 38(51):8055-8063. PubMed ID: 33187767
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potential use of inflammation and early immunological event biomarkers in assessing vaccine safety.
    Mastelic B; Lewis DJ; Golding H; Gust I; Sheets R; Lambert PH
    Biologicals; 2013 Mar; 41(2):115-24. PubMed ID: 23194656
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of the reactogenicity and immunogenicity of a split and a subunit-adjuvanted influenza vaccine in elderly subjects.
    Squarcione S; Sgricia S; Biasio LR; Perinetti E
    Vaccine; 2003 Mar; 21(11-12):1268-74. PubMed ID: 12559808
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Needle size for vaccination procedures in children and adolescents.
    Beirne PV; Hennessy S; Cadogan SL; Shiely F; Fitzgerald T; MacLeod F
    Cochrane Database Syst Rev; 2015 Jun; (6):CD010720. PubMed ID: 26086647
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adjuvant Systems for vaccines: 13 years of post-licensure experience in diverse populations have progressed the way adjuvanted vaccine safety is investigated and understood.
    Laupèze B; Hervé C; Di Pasquale A; Tavares Da Silva F
    Vaccine; 2019 Sep; 37(38):5670-5680. PubMed ID: 31420171
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influenza virus vaccine live intranasal--MedImmune vaccines: CAIV-T, influenza vaccine live intranasal.
    Drugs R D; 2003; 4(5):312-9. PubMed ID: 12952502
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Surveillance for safety after immunization: Vaccine Adverse Event Reporting System (VAERS)--United States, 1991-2001.
    Zhou W; Pool V; Iskander JK; English-Bullard R; Ball R; Wise RP; Haber P; Pless RP; Mootrey G; Ellenberg SS; Braun MM; Chen RT
    MMWR Surveill Summ; 2003 Jan; 52(1):1-24. PubMed ID: 12825543
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety-related regulatory actions for biologicals approved in the United States and the European Union.
    Giezen TJ; Mantel-Teeuwisse AK; Straus SM; Schellekens H; Leufkens HG; Egberts AC
    JAMA; 2008 Oct; 300(16):1887-96. PubMed ID: 18940975
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Testing human biologicals in animal host resistance models.
    Burleson GR; Burleson FG
    J Immunotoxicol; 2008 Jan; 5(1):23-31. PubMed ID: 18382855
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunogenicity, safety, and reactogenicity of the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine and DTPa-IPV-Hib when coadministered as a 3-dose primary vaccination schedule in The Netherlands: a randomized controlled trial.
    van den Bergh MR; Spijkerman J; François N; Swinnen K; Borys D; Schuerman L; Veenhoven RH; Sanders EA
    Pediatr Infect Dis J; 2011 Sep; 30(9):e170-8. PubMed ID: 21487327
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dose site reactions and related findings after vaccine administration in safety studies.
    Baldrick P
    J Appl Toxicol; 2016 Aug; 36(8):980-90. PubMed ID: 26968331
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Scientific review and recommendations on preclinical cardiovascular safety evaluation of biologics.
    Vargas HM; Bass AS; Breidenbach A; Feldman HS; Gintant GA; Harmer AR; Heath B; Hoffmann P; Lagrutta A; Leishman D; McMahon N; Mittelstadt S; Polonchuk L; Pugsley MK; Salata JJ; Valentin JP
    J Pharmacol Toxicol Methods; 2008; 58(2):72-6. PubMed ID: 18508287
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of cell substrates for the production of biologicals: Revision of WHO recommendations. Report of the WHO Study Group on Cell Substrates for the Production of Biologicals, 22-23 April 2009, Bethesda, USA.
    Knezevic I; Stacey G; Petricciani J; Sheets R;
    Biologicals; 2010 Jan; 38(1):162-9. PubMed ID: 19818645
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Managing unwanted immunogenicity of biologicals.
    Deehan M; Garcês S; Kramer D; Baker MP; Rat D; Roettger Y; Kromminga A
    Autoimmun Rev; 2015 Jul; 14(7):569-74. PubMed ID: 25742758
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety assessment of biotechnology-derived pharmaceuticals: ICH and beyond.
    Serabian MA; Pilaro AM
    Toxicol Pathol; 1999; 27(1):27-31. PubMed ID: 10367669
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictive markers of safety and immunogenicity of adjuvanted vaccines.
    Mastelic B; Garçon N; Del Giudice G; Golding H; Gruber M; Neels P; Fritzell B
    Biologicals; 2013 Nov; 41(6):458-68. PubMed ID: 24071553
    [TBL] [Abstract][Full Text] [Related]  

  • 17. From research to phase III: preclinical, industrial and clinical development of the Sanofi Pasteur tetravalent dengue vaccine.
    Guy B; Barrere B; Malinowski C; Saville M; Teyssou R; Lang J
    Vaccine; 2011 Sep; 29(42):7229-41. PubMed ID: 21745521
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Next Generation Vaccine Biomarkers workshop October 30-31, 2014--Ottawa, Canada.
    Twine SM; Fulton KM; Spika J; Ouellette M; Raven JF; Conlan JW; Krishnan L; Barreto L; Richards JC
    Hum Vaccin Immunother; 2015; 11(12):2923-30. PubMed ID: 26383909
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessment of nine candidate DTP-vaccines with reduced amount of antigen and/or without adjuvant as a fourth (booster-) dose in the second year of life.
    Knuf M; Habermehl P; Faber J; Bock HL; Sänger R; Bogaerts H; Clemens R; Schuind A; du Prel JB; Schmitt HJ
    Vaccine; 2006 Jul; 24(27-28):5627-36. PubMed ID: 16740348
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biologics safety preclinical, clinical and regulatory.
    Hennig R
    Expert Opin Drug Saf; 2003 Nov; 2(6):609-11. PubMed ID: 14585069
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.